Open-label, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device (Test) in Healthy Subjects

NCT02806219 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DEVICE: Prefilled syringe (PFS)
DEVICE: e-Device

Sponsor

UCB BIOSCIENCES, Inc.

Collaborators

[object Object]